Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome.
Abnormal fatty acid metabolism and dyslipidemia play an intimate role in the pathogenesis of metabolic syndrome and cardiovascular diseases. The availability of glucose and insulin predominate as upstream regulatory elements that operate through a collection of transcription factors to partition lipids toward anabolic pathways. The unraveling of the details of these cellular events has proceeded rapidly, but their physiologic relevance to lifestyle modification has been largely ignored. Here we highlight the role of dietary input, specifically carbohydrate intake, in the mechanism of metabolic regulation germane to metabolic syndrome. The key principle is that carbohydrate, directly or indirectly through the effect of insulin, controls the disposition of excess dietary nutrients. Dietary carbohydrate modulates lipolysis, lipoprotein assembly and processing and affects the relation between dietary intake of saturated fat intake and circulating levels. Several of these processes are the subject of intense investigation at the cellular level. We see the need to integrate these cellular mechanisms with results from low-carbohydrate diet trials that have shown reduced cardiovascular risk through improvement in hepatic, intravascular, and peripheral processing of lipoproteins, alterations in fatty acid composition, and reductions in other cardiovascular risk factors, notably inflammation. From the current state of the literature, however, low-carbohydrate diets are grounded in basic metabolic principles and the data suggest that some form of carbohydrate restriction is a candidate to be the preferred dietary strategy for cardiovascular health beyond weight regulation.
Volek
Jeff S
JS
Department of Kinesiology, University of Connecticut, 2095 Hillside Road, Unit 1110, Storrs, CT 06269-1110, United States. jeff.volek@uconn.edu
Fernandez
Maria Luz
ML
Feinman
Richard D
RD
Phinney
Stephen D
SD
D050197:Atherosclerosis / Q000378:metabolism*; D001786:Blood Glucose / Q000502:physiology; D008076:Cholesterol, HDL / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D004038:Diet, Reducing; D004040:Dietary Carbohydrates / Q000008:administration & dosage / Q000494:pharmacology*; D050171:Dyslipidemias / Q000378:metabolism*; D015444:Exercise / Q000502:physiology; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D006801:Humans; D007328:Insulin / Q000502:physiology; D007657:Ketone Bodies / Q000378:metabolism; D008297:Male; D024821:Metabolic Syndrome / Q000378:metabolism*; D014280:Triglycerides / Q000378:metabolism; D015431:Weight Loss / Q000502:physiology
D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004040:Dietary Carbohydrates; D005227:Fatty Acids; D007328:Insulin; D007657:Ketone Bodies; D014280:Triglycerides